Abstract
Treatment with an epidermal growth factor receptor inhibitor (egfri) in patients having non-small-cell lung cancer can cause frequent and diverse skin toxicities, an acneiform rash being one of the commonest. Although the exact pathophysiology of this rash and its development mechanisms remain unknown, investigators have noted that egfri-induced skin toxicity might be partly associated with sebaceous gland function. Sebum is composed mainly of the lipids squalene (sq), wax ester (we), triglyceride, free fatty acid, and cholesterol, which are secreted mostly from the sebaceous glands and by keratinocytes. We therefore investigated the lipid composition of sebum before and after administration of egfri and whether sebum composition was associated with the development of acneiform rash. To investigate any associated changes in sebum gland activity, we focused especially on alterations in the amounts of sq and we, which are secreted solely from the sebaceous glands. In contrast to our expectations, we observed no substantial changes in the lipid composition of sebum before and after administration of egfri. Composition varies with the individual; however, the proportion of sq and we derived from the sebaceous glands was significantly lower in regions that did not develop acneiform rash than in regions that did. Our results suggest that development of an acneiform rash after administration of egfri could be related to sebaceous gland activity. Measurement of the lipid composition of sebum before therapy with egfri might predict which patients will be prone to acneiform rash.
Highlights
Epidermal growth factor receptor inhibitor is increasingly being used in the treatment of nonsmall-cell lung cancer[1]
The lipid composition of sebum showed no substantial change after administration of egfri (Figure 1); we observed no change in the proportion of sq and we to total sebum lipids after egfri administration
Sebaceous gland dysfunction appears to contribute most to the eruptions, because the acneiform rash develops in the early phase of egfri treatment[5,7]
Summary
Epidermal growth factor receptor inhibitor (egfri) is increasingly being used in the treatment of nonsmall-cell lung cancer[1]. Administration of egfri often results in skin toxicity, and some reports indicate that such toxicity could be associated with a therapeutic response. A typical skin toxicity, is a relatively early-onset side effect, usually occurring after 1 week of treatment and reaching maximum intensity after 2–3 weeks. Investigators have noted that egfri-induced skin toxicity might be associated with the sebaceous glands, where epidermal growth factor receptor (egfr) is expressed[5]. No publications have looked into the development of skin toxicity with respect to skin physiology, such as sebum lipid profile. We investigated the association between the lipid composition of sebum and acneiform rash before and after administration of egfri
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
